Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Has Consensus Price Target of $36.46 According to Analysts

Key Points

• Analysts maintain a Moderate Buy consensus on Janux Therapeutics, with 10 buy ratings, one strong buy, two holds and two sells. The average 12-month price target is $36.46 versus the stock’s recent $18.50 price.
• Institutional investors and hedge funds own 75.39% of Janux shares, with several firms recently increasing their positions or initiating new stakes.
• Janux’s latest quarterly results missed expectations, reporting an adjusted loss of $0.35 per share versus the $0.25 consensus and revenue of $10.27 million compared with estimates of $19.07 million.

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $36.46.

Several equities analysts have issued reports on the company. Wolfe Research raised Janux Therapeutics from a "peer perform" rating to an "outperform" rating and set a $23.00 price target on the stock in a research note on Monday, August 24th. TD Cowen upgraded shares of Janux Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Truist Financial reiterated a "buy" rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. Guggenheim cut their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Janux Therapeutics in a report on Monday, July 20th.

Institutional Trading of Janux Therapeutics

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its stake in Janux Therapeutics by 67.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company's stock worth $28,000 after buying an additional 661 shares during the period. Versant Capital Management Inc grew its stake in Janux Therapeutics by 42.8% in the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company's stock valued at $40,000 after acquiring an additional 784 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Janux Therapeutics in the fourth quarter valued at approximately $51,000. Quantbot Technologies LP increased its holdings in shares of Janux Therapeutics by 2,290.0% during the second quarter. Quantbot Technologies LP now owns 5,497 shares of the company's stock valued at $84,000 after acquiring an additional 5,267 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $174,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Trading Up 3.2%

Shares of Janux Therapeutics stock opened at $18.50 on Friday. The business has a 50-day moving average price of $17.35 and a two-hundred day moving average price of $15.65. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The company has a market cap of $1.13 billion, a P/E ratio of -11.28 and a beta of 2.40.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.10). The firm had revenue of $10.27 million during the quarter, compared to the consensus estimate of $19.07 million. Equities research analysts forecast that Janux Therapeutics will post -1.7 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California, developing cancer immunotherapies designed to activate the immune system selectively within the tumor microenvironment. The company's technology is intended to direct T cells toward cancer cells while limiting activation in healthy tissues.

Janux's core technology platform, known as TRACTr, uses conditionally activated T-cell engager molecules designed to remain masked in circulation and become activated by proteases that are more prevalent in tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.